Preparation of highly sensitive monoclonal antibody against α-zearalanol based on the similar antigen determinant structure to zearalanone

In this study, we report a new method to prepare highly sensitive monoclonal antibody against α-zearalanol (ZAL) based on a similar antigen determinant structure. Zearalanone (ZAN), structural analogs of ZAL, was modified by oximation to obtain ZAN-O. ZAN-O was then coupled with bovine serum albumin using 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide (EDC) to synthesise the artificial complete antigen ZAN-O-BSA. ZAN-O-BSA was used to immunise the BALB/c mice. The splenocytes of the immunised mice were fused with myeloma NS0 cells. During the process of cell fusion, ZAL was used as an inhibitor instead of ZAN to screen the hybridoma cell lines that can secrete monoclonal antibodies against ZAL. The sensitivity (half inhibitory concentration, IC50) of the prepared monoclonal antibody was 0.475 ng/ml, the limit of detection (LOD) was 0.050 ng/ml, the linear range of detection was 0.066-3.399 ng/ml, the affinity constant Kaff was 6.18×107 l/mol, the cross-reactivity rate with structural analogues, such as β-zearalanol, α-zearalenol, β-zearalenol, ZAN and zearalenone were 28.07, 13.16, 15.83, 60.28 and 7.95% respectively. The cross-reactivity with other mycotoxin and carrier proteins were all less than 0.05%. The prepared monoclonal antibody can be used to establish a highly sensitive immunoassay for the detection of ZAL.

Adaptation of Cholesterol Requiring NS0 Cells to Serum Free Culture Conditions

Colorectal cancer is the third most common form of cancer and the second leading cause of cancer-related death in the Western world. The answers to such life threatening diseases and cancers are monoclonal antibodies (MAb's) which are widely used as therapeutic agents. World demand for currently approved MAb's is on the order of a few kilograms per year. However, new therapeutic MAb's are under development and require doses of several hundred milligrams to a gram over the course of therapy. Very often to cater for the special requirements for the growth of mammalian cells, serum is added to the cell culture medium. However, removal of serum from the cell culture medium is often carried out, especially if the end product is to be used for human consumption, in order to eliminate various disadvantages such as high physiological variability, high batch to batch variability, risk of contamination and high cost, and challenges posed in the downstream processing of the product. In this paper, the adaptation of cholesterol requiring NS0 cells to commercially available serum free media is presented. ABSTRAK: Kanser kolorektum merupakan kanser ketiga paling umum dan kini berada di tempat kedua penyebab kematian berkaitan kanser di negara Barat. Jawapan kepada penyakit yang mengancam nyawa dan penyakit kanser adalah antibodi monoklon (monoclonal antibodies ((MAb's)) yang digunakan sebagai agen terapeutik. Permintaan dunia terhadap MAb's yang diluluskan adalah dalam bilangan beberapa kilogram setahun. Namun, terapeutik MAb's yang baru adalah di bawah penyelidikan dan memerlukan beberapa ratus dos milligram hingga satu gram dalam satu peringkat terapi. Sering kali untuk memenuhi permintaan terhadap tumbesaran sel mamalia, serum dicampurkan dengan sel kultur perantara. Walaupun begitu, pemindahan serum dari sel kultur perantara sering dilakukan, terutamanya jika produk akhir digunakan untuk kegunaan manusia; untuk mengurangkan pelbagai kelemahan seperti kebolehubahan psikologi yang tinggi, kebolehubahan yang tinggi daripada satu kumpulan ke satu kumpulan lain, risiko pencemaran, kos yang tinggi, dan cabaran mendatang dalam pemprosesan produk. Dalam perbentangan ini, kolestrol yang diubah memerlukan sel NS0 yang dikomersilkan dengan serum bebas perantara.